Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

IPG is pretty much holding it together as it waits to complete its merger with Omnicom, reporting a 3.5% decline in organic ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who could benefit.

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...